Australia's Prana Charging Into Confirmatory Trials For Alzheimer's Drug That Looks To Alter Disease
This article was originally published in PharmAsia News
Executive Summary
PERTH, Australia - Melbourne-headquartered biotech Prana is gearing up to begin confirmatory trials for its lead molecule PBT2, an Alzheimer's disease treatment that has demonstrated surprising ability to reverse dementia symptoms